Silexion Therapeutics Corp
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (unaudited)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| 2026 | 2025 | |
|---|---|---|
| U.S. dollars in thousands | ||
| OPERATING EXPENSES: | ||
| Research and development (including $130 and $0 from related parties for the three-month periods ended March 31, 2026 and 2025, respectively) | $1,370 | $590 |
| General and administrative (including $215 and $21 from related parties for the three-month periods ended March 31, 2026 and 2025, respectively) | 1,379 | 1,060 |
| TOTAL OPERATING EXPENSES | 2,749 | 1,650 |
| OPERATING LOSS | ||
| Financial expense (income), net (including $(15) and $32 from related parties for the three-month periods ended March 31, 2026 and 2025, respectively) | (16) | 85 |
| LOSS BEFORE INCOME TAX | $2,733 | $1,735 |
| INCOME TAX | * | * |
| NET LOSS | $2,733 | $1,735 |
| LOSS PER SHARE, BASIC AND DILUTED | $0.85 | $3.84 |
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE | 3,230,378 | 451,990 |
** All share amounts have been adjusted (in the case of prior periods, retroactively) to reflect a 1-for-15 reverse share splits effected in July 2025, as discussed in Note 1(e)
F - 5
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.